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  Human immune response is compromised in space and incidence of urinary tract 
infections (UTI) in astronauts has been reported. We have found that the causative agent 
of UTI, the uropathogenic Escherichia coli, becomes more resistant to gentamicin (Gm), 
which is commonly used to treat this disease, under modeled microgravity conditions 
(MMG), the increase being controlled by the stress response master regulator, σs. While 
the wild type bacterium becomes virtually invincible under MMG, the strain missing this 
sigma factor barely survives. We report here preparatory ground work for testing this 
finding in space flight on a nanosatellite.  
  We have shown that the effect of Gm treatment on culture viability is directly correlated 
to increased Alamar Blue (AB) reduction; we have identified conditions to keep the 
experimental elements – the bacterial cultures, Gm, and AB – in a state of viability and 
potency to permit successful spaceflight experimentation given the necessary constraints. 
Spaceflight kinetics of AB reduction will be transmitted from the satellite via telemetry. 
  The PharmaSat hardware previously used for space experimentation with yeast was 
modified to permit studies with bacteria by reducing the filter pore size and increasing 
fluidics volume to enable more fluid exchanges. Several verification tests have been run 
using the nanosatellite’s flight software and prototype hardware. Cells were grown to 
stationary phase to induce the σs-controlled stress resistance and treated with Gm. 
Without Gm, the mutant took longer than the wild type to reduce the AB; this time 
difference increased almost 8 fold at 55 µg/mL Gm concentration. Thus, using flight 
hardware the mutant shows similarly increased sensitivity to Gm compared to the wild 
type to that found in our pilot microtiter plate experiments. Previous inflight experiments 
have given contradictory results concerning bacterial antibiotic resistance; none has yet 
explored the involvement of specific genes in this phenomenon. With our system ready to 
fly in late 2015/early 2016, these questions can be approached.  
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